New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
09:31 EDTTLOGTetraLogic has new opportunities, says Needham
Needham believes that TetraLogic's Phase I study of birinapant in patients chronically infected with hepatitis B opens up new opportunities for the company. The firm expects the stock to be boosted by data, expected in Q3, from a Phase I/II study in combination with a TRAIL receptor agonist in breast cancer. The firm keeps a Buy rating on the shares.
News For TLOG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
08:15 EDTTLOGTetraLogic announces publication of papers describing birinapant activity in HBV
TetraLogic Pharmaceuticals announced that research describing birinapant's preclinical activity in a mouse model of chronic human hepatitis B virus, or HBV, has been published in the journal Proceedings of the National Academy of Sciences. The publication reports preclinical studies performed at the Walter and Eliza Hall Institute of Medical Research, or WEHI, Melbourne, Australia in collaboration with TetraLogic Pharmaceuticals. In studies performed by Dr. Marc Pellegrini and his colleagues in mouse models of human hepatitis B, administration of birinapant resulted in loss of HBV-DNA, loss of HBsAg and the appearance of anti-HBsAg antibodies. A second paper describes similar results in mice where the targets of birinapant, cIAP1 and cIAP2, were ablated in the liver. That result provides independent genetic confirmation of birinapant's mechanism of action. These experiments provided the scientific rationale for TetraLogic's ongoing multiple ascending dose study of birinapant in subjects with chronic HBV. The trial is being conducted in subjects over the age of 18 with chronic HBV who are receiving treatment with either tenofovir or entecavir and who are HBsAg positive.
April 20, 2015
08:05 EDTTLOGTetraLogic, Merck enter into oncology clinical study collaboration
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use